UNITED STATES
SECURITIES & EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __)*
Xcyte Therapies, Inc.
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)
98389F309
(CUSIP Number)
October 29, 2004
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
13G is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
__________________
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for purposes of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
--------------------------------------------------------------------------------
Page 1
CUSIP No. 98389F309
(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Highbridge Capital Corporation
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [X]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands, British West Indies
--------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
-0-
SHARES -------------------------------------------------------------------
(6) SHARED VOTING POWER
BENEFICIALLY
6% Convertible Exchangeable Preferred Stock
OWNED BY (convertible into 1,842,545 shares of Common Stock).
See Item 4(a).
EACH -------------------------------------------------------------------
(7) SOLE DISPOSITIVE POWER
REPORTING -0-
-------------------------------------------------------------------
PERSON WITH (8) SHARED DISPOSITIVE POWER
See Row 6 above.
--------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
See Row 6 above.
--------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES **
[ ]
--------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
11.05% (See Item 4(b)).
--------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON
BD - Broker Dealer
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 2
CUSIP No. 98389F309
(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Highbridge International LLC
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [X]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands, British West Indies
--------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
-0-
SHARES -------------------------------------------------------------------
(6) SHARED VOTING POWER
BENEFICIALLY
6% Convertible Exchangeable Preferred Stock
OWNED BY (convertible into 1,842,545 shares of Common Stock).
See Item 4(a).
EACH -------------------------------------------------------------------
(7) SOLE DISPOSITIVE POWER
REPORTING -0-
-------------------------------------------------------------------
PERSON WITH (8) SHARED DISPOSITIVE POWER
See Row 6 above.
--------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
See Row 6 above.
--------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES **
[ ]
--------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
11.05% (See Item 4(b)).
--------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON
OO- Limited Liability Company
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 3
CUSIP No. 98389F309
(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Highbridge Capital Management, LLC
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [X]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
--------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
-0-
SHARES -------------------------------------------------------------------
(6) SHARED VOTING POWER
BENEFICIALLY
6% Convertible Exchangeable Preferred Stock
OWNED BY (convertible into 1,842,545 shares of Common Stock).
See Item 4(a).
EACH -------------------------------------------------------------------
(7) SOLE DISPOSITIVE POWER
REPORTING -0-
-------------------------------------------------------------------
PERSON WITH (8) SHARED DISPOSITIVE POWER
See Row 6 above.
--------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
See Row 6 above.
--------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES **
[ ]
--------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
11.05% (See Item 4(b)).
--------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON
00-Limited Liability Company
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 4
CUSIP No. 98389F309
(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Glenn Dubin
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [X]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
-0-
SHARES -------------------------------------------------------------------
(6) SHARED VOTING POWER
BENEFICIALLY
6% Convertible Exchangeable Preferred Stock
OWNED BY (convertible into 1,842,545 shares of Common Stock).
See Item 4(a).
EACH -------------------------------------------------------------------
(7) SOLE DISPOSITIVE POWER
REPORTING -0-
-------------------------------------------------------------------
PERSON WITH (8) SHARED DISPOSITIVE POWER
See Row 6 above.
--------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
See Row 6 above.
--------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES **
[ ]
--------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
11.05% (See Item 4(b)).
--------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 5
CUSIP No. 98389F309
(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Henry Swieca
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [X]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
-0-
SHARES -------------------------------------------------------------------
(6) SHARED VOTING POWER
BENEFICIALLY
6% Convertible Exchangeable Preferred Stock
OWNED BY (convertible into 1,842,545 shares of Common Stock).
See Item 4(a).
EACH -------------------------------------------------------------------
(7) SOLE DISPOSITIVE POWER
REPORTING -0-
-------------------------------------------------------------------
PERSON WITH (8) SHARED DISPOSITIVE POWER
See Row 6 above.
--------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
See Row 6 above.
--------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES **
[ ]
--------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
11.05% (See Item 4(b)).
--------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 6
Item 1.
(a) Name of Issuer
Xcyte Therapies, Inc., a Delaware corporation (the "Issuer")
(b) Address of Issuer's Principal Executive offices:
1124 Columbia Street, Suite 130
Seattle, Washington 98104
Item 2(a). Name of Person Filing
Item 2(b). Address of Principal Business office
Item 2(c). Citizenship
Highbridge Capital Corporation
The Cayman Corporate Centre, 4th Floor
27 Hospital Road
George Town, Grand Cayman
Cayman Islands, British West Indies
Citizenship: Cayman Islands, British West Indies
Highbridge International LLC
The Cayman Corporate Centre, 4th Floor
27 Hospital Road
George Town, Grand Cayman
Cayman Islands, British West Indies
Citizenship: Cayman Islands, British West Indies
Highbridge Capital Management, LLC
9 West 57th Street, 27th Floor
New York, New York 10019
Citizenship: State of Delaware
Glenn Dubin
c/o Highbridge Capital Management, LLC
9 West 57th Street, 27th Floor
New York, New York 10019
Citizenship: United States
Henry Swieca
c/o Highbridge Capital Management, LLC
9 West 57th Street, 27th Floor
New York, New York 10019
Citizenship: United States
(d) Title of Class of Securities
Common stock, par value $0.001 per share ("Common Stock")
(e) CUSIP Number 98389F309
Item 3. if this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check
whether the person filing is a:
(a) [ ] Broker or dealer registered under Section 15 of the Act
(15 U.S.C. 78o).
--------------------------------------------------------------------------------
Page 7
(b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in Section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) [ ] Investment company registered under Section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
(e) [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment
company under Section 3(c)(14) of the Investment Company Act of
1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Rule 13d-1(c), check this box. [x]
Item 4. Ownership
(a) Amount Beneficially Owned
As of the date hereof, each Reporting Person may be deemed the
beneficial owner of 1,842,545 shares of Common Stock issuable to
Highbridge International LLC upon conversion of 433,000 shares of 6%
Convertible Exchangeable Preferred Stock based on an initial conversion
price of $2.35. /1/
/1/ Highbridge Capital Management, LLC is the trading manager of
Highbridge International LLC and Highbridge Capital Corporation. Glenn
Dubin is a Managing Partner of Highbridge Capital Management, LLC.
Henry Swieca is a Managing Partner of Highbridge Capital Management,
LLC. Highbridge International LLC is a wholly-owned subsidiary of
Highbridge Capital Corporation, a broker/dealer. The foregoing should
not be construed in and of itself as an admission by any Reporting
Person as to beneficial ownership of shares of Common Stock owned by
another Reporting Person.
(b) Percent of Class
Approximately 11.05% as of the date of this Statement. (Based on the
Issuer's 424B3 Prospectus filed on November 1, 2004, there were
14,826,970 shares of Common Stock issued and outstanding after the
offering of 2,600,000 shares of 6% Convertible Exchangeable Preferred
Stock. In addition, 1,842,545 shares of Common Stock are issuable to
Highbridge International LLC upon conversion of the 6% Convertible
Exchangeable Preferred Stock described in Item 4(a) above.)
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
See Item 4(a) above.
(iii) sole power to dispose or to direct the disposition of
0
--------------------------------------------------------------------------------
Page 8
(iv) shared power to dispose or to direct the disposition of
See item (a) above.
Item 5. Ownership of Five Percent or Less of a Class
Inapplicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Inapplicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company
See Item 2 above.
Item 8. Identification and classification of Members of the Group
Inapplicable
Item 9. Notice of Dissolution of Group
Inapplicable
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose of effect.
--------------------------------------------------------------------------------
Page 9
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated this 8th day of November, 2004
Highbridge International LLC
By: /s/ Howard Feitelberg
----------------------------------------
Howard Feitelberg, Director
Highbridge Capital Corporation
By: /s/ Howard Feitelberg
----------------------------------------
Howard Feitelberg, Controller
Highbridge Capital Management, LLC
By: /s/ Ronald S. Resnick
----------------------------------------
Ronald S. Resnick, Managing Director
/s/ Glenn Dubin
----------------------------------
GLENN DUBIN
/s/ Henry Swieca
----------------------------------
HENRY SWIECA
--------------------------------------------------------------------------------
Page 10
Exhibit Index
Exhibit Description
1 Joint Filing Agreement
--------------------------------------------------------------------------------
Page 11
Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1)(iii) under the Securities
Exchange Act of 1934, as amended, the persons named below agree to the joint
filing on behalf of each of them of a Statement on schedule 13G filed on
November 8, 2004 (including amendments thereto) with respect to the common
stock of Xcyte Therapies, Inc.
This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
Dated: November 8, 2004
Highbridge International LLC
By: /s/ Howard Feitelberg
----------------------------------------
Howard Feitelberg, Director
Highbridge Capital Corporation
By: /s/ Howard Feitelberg
----------------------------------------
Howard Feitelberg, Controller
Highbridge Capital Management, LLC
By: /s/ Ronald S. Resnick
----------------------------------------
Ronald S. Resnick, Managing Director
/s/ Glenn Dubin
----------------------------------
GLENN DUBIN
/s/ Henry Swieca
----------------------------------
HENRY SWIECA
--------------------------------------------------------------------------------
Page 12